Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ:NTRB) is a pioneering health and pharmaceutical company headquartered in Oviedo, Florida, with a core focus on transdermal and topical technologies for product development. The company is well-known for its innovative approach to drug delivery, particularly through its proprietary AVERSA™ technology, which aims to prevent the abuse, misuse, diversion, and accidental exposure of transdermal patches containing drugs with abuse potential such as opioids.
Nutriband's flagship product is the AVERSA™ Fentanyl patch, which integrates its abuse-deterrent technology with an FDA-approved transdermal fentanyl patch. This breakthrough product is designed to address the serious issue of transdermal patch abuse and accidental pediatric exposure, which according to recent data, continues to result in major medical outcomes and even death. The AVERSA™ Fentanyl patch has the potential to be the first opioid patch with abuse-deterrent properties and is estimated to reach peak annual US sales of $80M - $200M.
The company's innovative approach includes a portfolio of abuse-deterrent transdermal products targeting drugs such as buprenorphine and methylphenidate, which are prone to the risk of abuse and misuse. Nutriband utilizes its proprietary taste aversion technology, which makes the patches unappealing and difficult to tamper with, thereby reducing the likelihood of recreational abuse or accidental ingestion by children.
In addition to its pharmaceutical advancements, Nutriband Inc. has expanded its portfolio through its wholly-owned subsidiary, Active Intelligence, which focuses on the manufacturing of Kinesiology Tapes and has partnered with major fitness brands like Reebok and Adidas.
Recent developments include the completion of an $8.4 million private placement to fund the commercial development of AVERSA™ Fentanyl and its anticipated NDA filing with the FDA in Q1 2025. This funding will support the pivotal laboratory and clinical studies required for regulatory approval. Nutriband intends to leverage the 505(b)(2) NDA regulatory pathway, which streamlines approval for drugs that have been previously approved, thereby reducing the need for extensive clinical trials.
For more detailed information, visit the company's website at www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced on March 2, 2023, that Alan Smith, Ph.D., COO and President of its subsidiary, 4P Therapeutics, was appointed to the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for transdermal delivery systems. This committee aims to enhance collaboration between the FDA and industry for developing safe generic products. Dr. Smith brings over 25 years of expertise in transdermal drug delivery systems. Nutriband focuses on developing innovative transdermal products, including its abuse-deterrent fentanyl patch, using proprietary AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced it has completed the necessary steps to submit its application to Ecuador's Health Register, allowing for the distribution of medical devices and cosmetic products in South America. This move opens access to the Andean Community, which includes four countries: Colombia, Ecuador, Peru, and Bolivia, with a combined population exceeding 114 million. Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse-deterrent fentanyl patch utilizing AVERSA™ technology. The company is navigating various risks associated with product development and regulatory approvals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will present at the RHK Capital Disruptive Growth Conference on December 5, 2022, at 10:20 AM in New York City. The presentation will focus on the company's AVERSA technology and its market potential. The conference will host executives from up to 30 growth-oriented companies, engaging with institutional investors and financial advisors. Nutriband specializes in transdermal pharmaceutical products, with a lead product under development being an abuse deterrent fentanyl patch utilizing AVERSA technology.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
What is the AVERSA™ Fentanyl patch?
What recent achievements has Nutriband Inc. made?
What partnerships does Nutriband Inc. have?
What are the potential market sales for AVERSA™ Fentanyl?
What is the significance of the 505(b)(2) NDA regulatory pathway for Nutriband?
How does Nutriband address accidental pediatric exposure to fentanyl patches?
What other products are in Nutriband’s development pipeline?
Where can I get more information about Nutriband Inc.?
